KURA gets $30M from Kyowa Kirin on ziftomenib Phase 3 start

Rhea-AI Filing Summary

Kura Oncology announced receipt of a $30 million milestone payment from Kyowa Kirin. The payment was triggered by dosing the first patient in KOMET-017, a pair of Phase 3 registrational trials evaluating ziftomenib, a once-daily, investigational oral menin inhibitor.

KOMET-017 consists of two independent, global, randomized double-blind, placebo-controlled Phase 3 studies. They assess ziftomenib in combination with intensive and non‑intensive chemotherapy in adults with newly diagnosed NPM1‑mutated or KMT2A‑rearranged acute myeloid leukemia. The payment provides non-dilutive funding aligned with the advancement of ziftomenib into late‑stage testing.

Insights

Biotech partnerships & clinical milestones

$30M milestone received as Phase 3 dosing begins; cash-in, clinical risk persists.

The collaboration with Kyowa Kirin includes milestone payments tied to development events. First patient dosing in the Phase 3 KOMET-017 program activated a $30 million payment to Kura Oncology, adding non-dilutive cash as ziftomenib advances.

KOMET-017 comprises two global, randomized, double-blind, placebo-controlled trials testing ziftomenib with intensive and non‑intensive chemotherapy in newly diagnosed NPM1‑mutated or KMT2A‑rearranged AML. While the cash inflow is clear, outcomes and regulatory paths remain dependent on Phase 3 results.

The immediate, tangible effect is the milestone receipt; subsequent impact depends on trial conduct and readouts, which are not detailed in the excerpt.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Understanding 8-K Material Events →

false 0001422143 0001422143 2025-10-24 2025-10-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 24, 2025

KURA ONCOLOGY, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-37620		61-1547851
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
4930 Directors Place, Suite 500, San Diego, CA				92121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 500-8800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		KURA		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 24, 2025, Kura Oncology, Inc. (the “Company”) announced receipt of a $30 million milestone payment under its Collaboration and License Agreement with Kyowa Kirin, Inc. and Kyowa Kirin Co., Ltd. (together,“Kyowa Kirin”) in connection with the dosing of the first patient in the KOMET-017 Phase 3 registrational trials of ziftomenib, a once-daily, investigational oral menin inhibitor. The Company and Kyowa Kirin announced the launch of the KOMET-017 trials on September 29, 2025.

KOMET-017 (NCT07007312) comprises two independent, global, randomized double-blind, placebo-controlled Phase 3 trials to evaluate ziftomenib in combination with both intensive and non-intensive chemotherapy regimens in patients with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Kura Oncology, Inc.
Date: October 24, 2025				By:		/s/ Teresa Bair
						Teresa Bair
						Chief Legal Officer

FAQ

What did Kura Oncology (KURA) announce in this update?

Kura Oncology announced receipt of a $30 million milestone payment from Kyowa Kirin.

What triggered the $30 million payment to KURA?

Dosing of the first patient in the Phase 3 registrational KOMET-017 trials of ziftomenib.

What is being studied in KOMET-017?

Ziftomenib, an investigational once‑daily oral menin inhibitor, combined with intensive and non‑intensive chemotherapy in newly diagnosed NPM1‑mutated or KMT2A‑rearranged AML.

How many Phase 3 studies are in KOMET-017?

Two independent, global, randomized, double‑blind, placebo‑controlled trials.

Who is Kura Oncology’s partner on ziftomenib?

Kyowa Kirin, Inc. and Kyowa Kirin Co., Ltd.

When was KOMET-017 launched?

Kura Oncology and Kyowa Kirin announced the launch on September 29, 2025.